Home pagePTKFY • OTCMKTS
add
PT Kalbe Farma Unsponsored Indonesia ADR
Chiusura precedente
18,84Â $
Intervallo annuale
11,44Â $ - 23,73Â $
Cap di mercato
65,86Â Bln IDR
Volume medio
286,00
Notizie del mercato finanziario
Dati finanziari
Conto economico
Entrate
Utile netto
(IDR) | mar 2025info | Variazione Y/Y |
---|---|---|
Entrate | 8,85Â Bln | 5,77% |
Spese di gestione | 2,24Â Bln | 9,58% |
Utile netto | 1,08Â Bln | 12,45% |
Margine di profitto netto | 12,17 | 6,29% |
Utili per azione | 23,57 | 13,86% |
EBITDA | 1,57Â Bln | 11,60% |
Aliquota fiscale effettiva | 22,83% | — |
Stato patrimoniale
Totale attivo
Totale passivo
(IDR) | mar 2025info | Variazione Y/Y |
---|---|---|
Investimenti cash/breve termine | 4,69Â Bln | 10,74% |
Totale attivo | 30,58Â Bln | 5,59% |
Totale passivo | 5,22Â Bln | 7,63% |
Patrimonio netto totale | 25,36 Bln | — |
Azioni in circolazione | 45,65 Mld | — |
Prezzo/valore contabile | 0,04 | — |
Redditività dell'attivo | 11,54% | — |
Rendimento sul capitale | 13,57% | — |
Flusso di cassa
Flusso di cassa netto
(IDR) | mar 2025info | Variazione Y/Y |
---|---|---|
Utile netto | 1,08Â Bln | 12,45% |
Liquidità di esercizio | 344,56 Mld | -71,44% |
Contanti da investimenti | -118,66Â Mld | 61,24% |
Contanti da finanziamenti | -423,13Â Mld | -791,88% |
Flusso di cassa netto | -180,46Â Mld | -121,28% |
Flusso di cassa libero | -102,67Â Mld | -114,36% |
Informazioni
PT Kalbe Farma Tbk, or simply known as Kalbe, is an Indonesian pharmaceutical, healthcare and nutrition company established in 1966. The company has expanded by strategic acquisitions of pharmaceutical companies, becoming an integrated consumer health and nutrition enterprise.
The Kalbe Group has brands in the prescription drugs, OTC drugs, energy drink and nutrition products, distribution arm that reaches over 1 million outlets. Notably, the company produces misoprostol, a drug which is used to treat stomach ulcers but is also widely used in Indonesia as an illegal abortifacient.
Company brands in healthcare and pharmaceutical segments include Promag, Mixagrip, Woods, Komix, Diabetasol, Prenagen, Extra Joss and Fitbar.
Kalbe is the largest publicly listed pharmaceutical company in Southeast Asia with around US$5 billion in market capitalization and revenues of over Rp 15 trillion. The name "Kalbe" is a syllabic abbreviation of its founder's name: Khouw Lip Boen. Wikipedia
Fondazione
10 set 1966
Sito web
Dipendenti
12.841